Agilent Technologies, Inc. (NYSE:A) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Agilent Technologies, Inc. (NYSE:A) have earned an average recommendation of “Moderate Buy” from the twenty research firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $170.3333.

Several equities research analysts have issued reports on A shares. Wolfe Research restated a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Wells Fargo & Company dropped their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Royal Bank Of Canada upped their price target on shares of Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. HSBC decreased their price objective on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Jefferies Financial Group initiated coverage on shares of Agilent Technologies in a research report on Thursday, July 9th. They issued a “hold” rating and a $135.00 target price for the company.

Hedge Funds Weigh In On Agilent Technologies

Large investors have recently bought and sold shares of the business. Greenleaf Trust grew its position in shares of Agilent Technologies by 0.8% during the second quarter. Greenleaf Trust now owns 8,117 shares of the medical research company’s stock worth $1,078,000 after acquiring an additional 68 shares during the last quarter. Nilsine Partners LLC boosted its stake in Agilent Technologies by 0.8% during the 2nd quarter. Nilsine Partners LLC now owns 9,650 shares of the medical research company’s stock valued at $1,282,000 after purchasing an additional 72 shares during the period. Fiduciary Trust Co boosted its stake in Agilent Technologies by 1.6% during the 3rd quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock valued at $633,000 after purchasing an additional 77 shares during the period. Sapient Capital LLC grew its position in Agilent Technologies by 4.2% in the 1st quarter. Sapient Capital LLC now owns 2,105 shares of the medical research company’s stock worth $240,000 after purchasing an additional 85 shares during the last quarter. Finally, Plan A Wealth LLC increased its stake in shares of Agilent Technologies by 3.2% in the fourth quarter. Plan A Wealth LLC now owns 2,959 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 92 shares during the period.

Agilent Technologies Stock Performance

NYSE A opened at $153.79 on Tuesday. The business’s 50-day simple moving average is $140.85 and its 200-day simple moving average is $127.21. The firm has a market capitalization of $43.43 billion, a P/E ratio of 30.27, a P/E/G ratio of 2.34 and a beta of 1.25. Agilent Technologies has a 1-year low of $108.35 and a 1-year high of $163.75. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.05 and a quick ratio of 1.56.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The firm had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. During the same period in the prior year, the firm earned $1.37 EPS. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts predict that Agilent Technologies will post 6.2 EPS for the current year.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.